ORIC Pharmaceuticals, Inc.

NASDAQ:ORIC

Biotechnology

Healthcare
$7.70 -0.75%

-$0.07 today

Market cap
$800.27M
Beta
1.06
P/E (TTM)
-6.7
EPS (TTM)
-$1.28
52W Low $7.23High $14.93

Volume 1.07M

Average 1.91M

Returns on capital

ORIC Pharmaceuticals, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-33.7%

avg -34.3%

ROIC

-36.3%

avg -44.1%

ROA

-31.5%

avg -39.1%

Analysis

ROA is currently the strongest return metric at -31.5% versus its period average of -39.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Jacob Chacko

President, Chief Executive Officer & DirectorUSD 1.11M47112.50K0.11%

Pratik S. Multani

Chief Medical OfficerUSD 774.94K5935.50K0.03%

Dominic G. Piscitelli

Chief Financial OfficerUSD 729.92K51——

Richard A. Heyman

Founder, Independent Chairman & Member of Scientific Advisory BoardUSD 100K6926.70K0.03%

Scott W. Lowe

Founder & Member of Scientific Advisory Board————

Christian V. Kuhlen

General Counsel & Chief Compliance Officer—53——

Edna Chow Maneval

Executive Vice President of Clinical Development—65——

Kevin Brodbeck

Chief Technical Officer————

Daniel Iazzetti

Vice President & Head of People————

Charles L. Sawyers

Founder & Member of Scientific Advisory Board—67——

Lori Sickels Friedman

Chief Scientific Officer—61——

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 1, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

16

$2.96M

Net Transaction Value

−$2.96M

Net selling

Most Active

Piscitelli Dominic

7 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Oct 20, 26

Piscitelli Dominic

Direct

Sell$189.4K
Oct 1, 26

Heyman Richard A.

Direct

Sell$45.2K
Oct 1, 26

Heyman Richard A.

Indirect

Sell$41.3K
Sep 28, 26

Piscitelli Dominic

Direct

Sell$181.3K
Sep 24, 26

Piscitelli Dominic

Direct

Sell$1.4K
Sep 24, 26

Piscitelli Dominic

Direct

Sell$6.8K
Aug 26, 26

Piscitelli Dominic

Direct

Sell$1.1M
Jul 24, 26

Heyman Richard A.

Indirect

Sell$73.3K
Jul 24, 26

Heyman Richard A.

Direct

Sell$84.1K
Jul 6, 26

Heyman Richard A.

Indirect

Sell$3.6K

1–10 of 16

Summary

Insiders reported 0 buys worth $0.00 and 16 sells worth $2.96M over the last 12 months. That adds up to net selling of $2.96M. Piscitelli Dominic was the most active insider with 7 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A5 analysts
RevenueN/AN/AN/A
N/A4 analysts
Net IncomeN/AN/AN/A
N/A4 analysts
EBITN/AN/AN/A
N/A4 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does ORIC Pharmaceuticals, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about ORIC's management, answered from reported figures.

Who manages ORIC?

ORIC Pharmaceuticals, Inc. (ORIC) lists 11 active executives. The top listed executive is Scott W. Lowe, Founder & Member of Scientific Advisory Board.

Are ORIC insiders buying or selling?

Recent insider activity shows net buying of $9.46M.